AU · rank #1 · 2026-07-21
NUTX
NASDAQ · $1.12B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 3.348 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.58 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 2 |
| Insider signal (90d) $0 across 0 unique buyers. | -0.163 |
| Analyst upside Consensus target $246.40 | +52.6% |
| Momentum acceleration 3-month minus 12-month momentum. | +37.67% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.67 |
| Gross margin TTM | +50.6% |
| 52w high | $204.00 |
| Market cap (USD) | $1.12B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Nutex Health Inc. is a physician-led, technology-enabled healthcare services company that operates approximately 27 micro-hospitals and hospital outpatient departments across 12 states alongside a population health management division [RECENT_DEVELOPMENTS, BUSINESS_STATUS].
Rationale
The quant model's 52.6% analyst upside and 100% revision agreement are supported by Q1 2026 earnings doubling year-over-year, robust operating cash flow of $75.5 million, and active share repurchase programs [RECENT_DEVELOPMENTS].
Material risks
- 1Heavy reliance on No Surprises Act arbitration for reimbursement disputes exposes the company to regulatory volatility and rising Independent Dispute Resolution (IDR) expenses, which recently dragged Q1 2026 adjusted EBITDA down by 21% [RECENT_DEVELOPMENTS].
- 2The shift to internally funding new hospital construction prior to anticipated sale-leaseback transactions could tie up cash and strain liquidity if construction delays or unfavorable financing terms emerge [RECENT_DEVELOPMENTS].
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.